176 related articles for article (PubMed ID: 31391294)
21. Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression.
Chen RL; Zhao J; Zhang XC; Lou NN; Chen HJ; Yang X; Su J; Xie Z; Zhou Q; Tu HY; Zhong WZ; Yan HH; Guo WB; Wu YL; Yang JJ
BMC Cancer; 2018 Nov; 18(1):1171. PubMed ID: 30477470
[TBL] [Abstract][Full Text] [Related]
22. Comparative Genomic Profiling of Refractory and Metastatic Penile and Nonpenile Cutaneous Squamous Cell Carcinoma: Implications for Selection of Systemic Therapy.
Jacob JM; Ferry EK; Gay LM; Elvin JA; Vergilio JA; Ramkissoon S; Severson E; Necchi A; Killian JK; Ali SM; Schrock AB; Liu NW; Chung J; Miller VA; Stephens PJ; Welsh A; Corona RJ; Ross JS; Bratslavsky G
J Urol; 2019 Mar; 201(3):541-548. PubMed ID: 30291913
[TBL] [Abstract][Full Text] [Related]
23. Emergence of Preexisting MET Y1230C Mutation as a Resistance Mechanism to Crizotinib in NSCLC with MET Exon 14 Skipping.
Ou SI; Young L; Schrock AB; Johnson A; Klempner SJ; Zhu VW; Miller VA; Ali SM
J Thorac Oncol; 2017 Jan; 12(1):137-140. PubMed ID: 27666659
[TBL] [Abstract][Full Text] [Related]
24. Identification of genomic mutations associated with clinical outcomes of induction chemotherapy in patients with head and neck squamous cell carcinoma.
Ock CY; Son B; Keam B; Lee SY; Moon J; Kwak H; Kim S; Kim TM; Jeon YK; Kwon SK; Hah JH; Lee SH; Kwon TK; Kim DW; Wu HG; Sung MW; Heo DS
J Cancer Res Clin Oncol; 2016 Apr; 142(4):873-83. PubMed ID: 26677030
[TBL] [Abstract][Full Text] [Related]
25. Case report: Prompt response to radiotherapy and chemotherapy combined with crizotinib in gingival sarcomatoid squamous cell carcinoma with MET 14 mutation.
Sun Z; Xia B; Zhang M; Xu S; Ma Y; Zhang X
Front Oncol; 2022; 12():1006516. PubMed ID: 36147925
[TBL] [Abstract][Full Text] [Related]
26. Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial.
Schöffski P; Wozniak A; Escudier B; Rutkowski P; Anthoney A; Bauer S; Sufliarsky J; van Herpen C; Lindner LH; Grünwald V; Zakotnik B; Lerut E; Debiec-Rychter M; Marréaud S; Lia M; Raveloarivahy T; Collette S; Albiges L
Eur J Cancer; 2017 Dec; 87():147-163. PubMed ID: 29149761
[TBL] [Abstract][Full Text] [Related]
27. Treatment patterns and outcomes among patients with recurrent/metastatic squamous cell carcinoma of the head and neck.
Nadler E; Joo S; Boyd M; Black-Shinn J; Chirovsky D
Future Oncol; 2019 Mar; 15(7):739-751. PubMed ID: 30511880
[TBL] [Abstract][Full Text] [Related]
28. Targeting
Robinson H; Green M; Radkar G; Ready N; Strickler J
Cancer Invest; 2021 Mar; 39(3):235-239. PubMed ID: 33538211
[TBL] [Abstract][Full Text] [Related]
29. Clinical Benefit in Response to Palbociclib Treatment in Refractory Uterine Leiomyosarcomas with a Common
Elvin JA; Gay LM; Ort R; Shuluk J; Long J; Shelley L; Lee R; Chalmers ZR; Frampton GM; Ali SM; Schrock AB; Miller VA; Stephens PJ; Ross JS; Frank R
Oncologist; 2017 Apr; 22(4):416-421. PubMed ID: 28283584
[TBL] [Abstract][Full Text] [Related]
30. Mutations of the LIM protein AJUBA mediate sensitivity of head and neck squamous cell carcinoma to treatment with cell-cycle inhibitors.
Zhang M; Singh R; Peng S; Mazumdar T; Sambandam V; Shen L; Tong P; Li L; Kalu NN; Pickering CR; Frederick M; Myers JN; Wang J; Johnson FM
Cancer Lett; 2017 Apr; 392():71-82. PubMed ID: 28126323
[TBL] [Abstract][Full Text] [Related]
31. Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial.
Machiels JP; Haddad RI; Fayette J; Licitra LF; Tahara M; Vermorken JB; Clement PM; Gauler T; Cupissol D; Grau JJ; Guigay J; Caponigro F; de Castro G; de Souza Viana L; Keilholz U; Del Campo JM; Cong XJ; Ehrnrooth E; Cohen EE;
Lancet Oncol; 2015 May; 16(5):583-94. PubMed ID: 25892145
[TBL] [Abstract][Full Text] [Related]
32. Genomic Profiling of Parathyroid Carcinoma Reveals Genomic Alterations Suggesting Benefit from Therapy.
Kang H; Pettinga D; Schubert AD; Ladenson PW; Ball DW; Chung JH; Schrock AB; Madison R; Frampton GM; Stephens PJ; Ross JS; Miller VA; Ali SM
Oncologist; 2019 Jun; 24(6):791-797. PubMed ID: 30373905
[TBL] [Abstract][Full Text] [Related]
33. Mutation tracking of a patient with EGFR-mutant lung cancer harboring de novo MET amplification: Successful treatment with gefitinib and crizotinib.
Zheng X; Zhang G; Li P; Zhang M; Yan X; Zhang X; Yang J; Li H; Liu X; Ma Z; Wang H
Lung Cancer; 2019 Mar; 129():72-74. PubMed ID: 30797494
[TBL] [Abstract][Full Text] [Related]
34. Genomic alterations in human epidermal growth factor receptor 2 (HER2/ERBB2) in head and neck squamous cell carcinoma.
Chung CH; Germain A; Subramaniam RM; Heilmann AM; Fedorchak K; Ali SM; Miller VA; Palermo RA; Fakhry C
Head Neck; 2017 Jan; 39(1):E15-E19. PubMed ID: 27653501
[TBL] [Abstract][Full Text] [Related]
35. Head and neck squamous cell carcinoma: Genomics and emerging biomarkers for immunomodulatory cancer treatments.
Solomon B; Young RJ; Rischin D
Semin Cancer Biol; 2018 Oct; 52(Pt 2):228-240. PubMed ID: 29355614
[TBL] [Abstract][Full Text] [Related]
36. Heterogeneous responses and resistant mechanisms to crizotinib in ALK-positive advanced non-small cell lung cancer.
Kang J; Chen HJ; Zhang XC; Su J; Zhou Q; Tu HY; Wang Z; Wang BC; Zhong WZ; Yang XN; Chen ZH; Ding Y; Wu X; Wang M; Fu JG; Yang Z; Zhang X; Shao YW; Wu YL; Yang JJ
Thorac Cancer; 2018 Sep; 9(9):1093-1103. PubMed ID: 29978950
[TBL] [Abstract][Full Text] [Related]
37. PDK1 Mediates
Sambandam V; Frederick MJ; Shen L; Tong P; Rao X; Peng S; Singh R; Mazumdar T; Huang C; Li Q; Pickering CR; Myers JN; Wang J; Johnson FM
Clin Cancer Res; 2019 Jun; 25(11):3329-3340. PubMed ID: 30770351
[TBL] [Abstract][Full Text] [Related]
38. Patient-Derived Xenografts for Prognostication and Personalized Treatment for Head and Neck Squamous Cell Carcinoma.
Karamboulas C; Bruce JP; Hope AJ; Meens J; Huang SH; Erdmann N; Hyatt E; Pereira K; Goldstein DP; Weinreb I; Su J; O'Sullivan B; Tiedemann R; Liu FF; Pugh TJ; Bratman SV; Xu W; Ailles L
Cell Rep; 2018 Oct; 25(5):1318-1331.e4. PubMed ID: 30380421
[TBL] [Abstract][Full Text] [Related]
39. Clinically advanced and metastatic pure mucinous carcinoma of the breast: a comprehensive genomic profiling study.
Ross JS; Gay LM; Nozad S; Wang K; Ali SM; Boguniewicz A; Khaira D; Johnson A; Elvin JA; Vergilio JA; Suh J; Miller VA; Stephens PJ
Breast Cancer Res Treat; 2016 Jan; 155(2):405-13. PubMed ID: 26762307
[TBL] [Abstract][Full Text] [Related]
40. Functional Genomics Uncover the Biology behind the Responsiveness of Head and Neck Squamous Cell Cancer Patients to Cetuximab.
Bossi P; Bergamini C; Siano M; Cossu Rocca M; Sponghini AP; Favales F; Giannoccaro M; Marchesi E; Cortelazzi B; Perrone F; Pilotti S; Locati LD; Licitra L; Canevari S; De Cecco L
Clin Cancer Res; 2016 Aug; 22(15):3961-70. PubMed ID: 26920888
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
